Early diagnosis of congestive heart failure: Clinical utility of B-type natriuretic peptide testing associated with Doppler echocardiography

Journal of Cardiovascular Medicine

Volumn 7, Issue 6, 2006, Pages 406-413

  Aspromonte, Nadia ^a,d   Feola, Mauro ^b   Scardovi, Angela Beatrice ^a   Coletta, Claudio ^a   D'Eri, Alessandra ^c   Giovinazzo, Prospero ^c   Carunchio, Alessandro ^a   Chiera, Antonella ^a   Fanelli, Renato ^d   Giacomo, Tiziana Di ^a   Ricci, Roberto ^a   Ceci, Vincenzo ^a   Milani, Loredano ^c   Valle, Roberto ^c  

^a SPIRITO SANTO HOSPITAL   (Italy)

^b S Croce e Carle City Hospital   (Italy)

^c Civic Hospital   (Italy)

^d Local Health Unit RM ^*  (Italy)

Author keywords

B type natriuretic peptide; Congestive heart failure; Cost containment; Diagnosis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

AGED; ARTICLE; CARDIOLOGIST; CLINICAL EXAMINATION; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIASTOLE; DOPPLER ECHOCARDIOGRAPHY; EARLY DIAGNOSIS; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT CODING; PATIENT REFERRAL; PRIMARY MEDICAL CARE; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYMPTOMATOLOGY; SYSTOLE; TRANSTHORACIC ECHOCARDIOGRAPHY;

AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY, DOPPLER; ELECTROCARDIOGRAPHY; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; PROSPECTIVE STUDIES; RADIOGRAPHY, THORACIC; REFERRAL AND CONSULTATION; ROC CURVE; STATISTICS, NONPARAMETRIC;

EID: 33746589556     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/01.JCM.0000228690.40452.d3     Document Type: Article

References (44)

1. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993; 22 (suppl A):6A-13A.
2. Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole-Wilson PA, Sutton GC, et al. The epidemiology of heart failure. Eur Heart J 1997; 18:208-225.
3. Vinson JM, Rich MW, Sperry JC, Shah AS, McNamara T. Early readmission of elderly patients with congestive heart failure. J Am Geriatric Soc 1990; 38:1290-1295.
4. Valle R, Chinellato M, Gallo G, Milani L. Heart failure in nursing homes: prevalence, hospitalization, compliance to guidelines. Ital Heart J Suppl 2001; 2:772-774.
5. McMurray JJ, Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart 2000; 83:596-602.
6. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26:1115-1140.
7. Remes J, Tikkanen I, Fyhrquist F, Pyorala K. Neuroendocrine activity in untreated heart failure. Br Heart J 1991; 65:249-255.
8. Tsutsamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96:509-516.
9. Chen HH, Burnett JC. Natriuretic peptides in the pathophysiology of congestive heart failure. Curr Cardiol Rep 2000; 2:198-205.
10. Vasan RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PW, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA 2002; 288:1252-1259.
11. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998; 135 (Pt 1):825-832.
12. Dao Q, Krishnaswamy P, Kazanegra R, Harrison A, Amirnovin R, Lenert L, et al. Utility of B-type natriuretic peptide (BNP) in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001; 37:379-385.
13. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al., for the Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347:161-167.
14. McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 351:9-13.
15. McClure SJ, Caruana L, Davie AP, Goldthorp S, McMurray JJ. Cohort study of plasma natriuretic peptides for identifying left ventricular systolic dysfunction in primary care. BMJ 1998; 317:516-519.
16. Landray MJ, Lehman R, Arnold I. Measuring brain natriuretic peptide in suspected left ventricular systolic dysfunction in general practice: cross-sectional study. BMJ 2000; 320:985-986.
17. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation; endorsed by the Heart Rhythm Society. Circulation 2005; 112:1825-1852.
18. Italian Collaborative Group on BNP in Heart Failure. Consensus document. B-type natriuretic peptide in the Italian cardiology clinical reality: update of the experience. Ital Heart J Suppl 2003; 4:850-861.
19. Krishnaswamy PK, Lubien E, Clopton P, Koon J, Kazanegra R, Wanner E, et al. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med 2001; 111:274-279.
20. Lubien E, DeMaria A, Krishnaswamy P, Clopton P, Koon J, Kazanegra R, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 2002; 105:595-601.
21. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971; 285:1441-1446.
22. Italian Ministry of Health. Revisione del nomenclatore tariffario delle prestazioni specialistiche ambulatoriali. Ministry Decree November 7, 1991.
23. McCullough PA, Philbin EF, Spertus JA, Kaatz S, Sandberg KR, Weaver WD, for the Resource Utilization Among Congestive Heart Failure (REACH) Study. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol 2002; 39:60-69.
24. Sparrow N, Adlam D, Cowley A, Hampton JR. Difficulties of introducing the National Service Framework for heart failure into general practice in the UK. Eur J Heart Fail 2003; 5:355-361.
25. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334:1349-1355.
26. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353:9-13.
27. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353:2001-2007.
28. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709-717.
29. CONSENSUS Trial Study Group. Effect of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316:1429-1435.
30. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302.
31. Frigerio M, Oliva F, Turazza FM, Bonow RO. Prevention and management of chronic heart failure in management of asymptomatic patients. Am J Cardiol 2003; 91 (suppl):4F-9F.
32. Misuraca G, Serafini O, Caporale R, Battista F, Plastina F. Diagnosis of heart failure in general medicine: role of cerebral natriuretic peptide. Results of a pilot study of a population sample from Calabria. Ital Heart J Suppl 2002; 3:928-932.
33. McMurray JV, McDonagh TA, Davie AP, Cleland JG, Francis CM, Morrison C. Should we screen for asymptomatic left ventricular dysfunction to prevent heart failure? Eur Heart J 1998; 19:842-846.
34. Francis CM, Caruana L, Kearney P, Love M, Sutherland GR, Starkey IR, et al. Open access echocardiography in management of heart failure in the community. BMJ 1995; 310:634-636.
35. Bozkurt B, Mann DL. Use of biomarkers in the management of heart failure: are we there yet? Circulation 2003; 107:1231-1233.
36. Emdin M, Clerico A, Clemenza F, Galvani M, Latini R, Masson R, et al. Recommendations for the clinical use of cardiac natriuretic peptides. Ital Heart J 2005; 6:430-446.
37. Clerico A, Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin Chem 2004; 50:33-50.
38. Doust JA, Glasziou PP, Pietrzak E, Dobson AJ. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Intern Med 2004; 164:1978-1984.
39. Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 2002; 39:202-209.
40. Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350:1349-1353.
41. Smith H, Pickering RM, Struthers A, Simpson I, Mant D. Biochemical diagnosis of ventricular dysfunction in elderly patients in general practice: observational study. BMJ 2000; 320:906-908.
42. Pinamonti B, Di Lenarda A, Sinagra G, Camerini F. Restrictive left ventricular filling pattern in dilated cardiomyopathy assessed by Doppler echocardiography: clinical, echocardiographic and hemodynamic correlations and prognostic implications. Heart Muscle Disease Study Group. J Am Coll Cardiol 1993; 22:808-815.
43. Sparrow N, Adlam D, Cowley A, Hampton JR. The diagnosis of heart failure in general practice: implications for the UK National Service Framework. Eur J Heart Fail 2003; 5:349-354.
44. Nielsen OW, McDonagh TA, Robb SD, Dargie HJ. Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. J Am Coll Cardiol 2003; 41:113-120.